NAD+ IV therapy is one of the wellness industry’s best marketing stories: a fundamental cellular molecule, declining with age, dripped straight into your veins to restore youth and energy. The molecule is real and genuinely important. The drip’s evidence is where the story falls apart — and where an honest read can save you several hundred dollars a session.
$250–$1,500
Typical cost per IV session (US)
wellness-clinic pricing
0
Controlled outcome trials of IV NAD+ for anti-aging/energy
PubMed
Oral
Where the real human NAD+ evidence is
NR/NMN RCTs
What is NAD+ IV therapy?
NAD+ IV therapy is an intravenous infusion of nicotinamide adenine dinucleotide, given in a clinic or wellness bar over anything from 45 minutes to several hours, typically across a course of consecutive days. The NAD+ itself is prepared by a compounding pharmacy rather than manufactured as an approved drug, and doses in the published literature cluster around 500 mg per session.[4] The pitch is straightforward: NAD+ falls with age, so putting it directly into the bloodstream should restore what time removed. Everything contested about the treatment sits in that final step.
The molecule is real; the drip’s evidence isn’t
NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme in cellular energy metabolism, and its levels do fall with age — that part is solid biology. The leap is the delivery. The rigorous human evidence on raising NAD+ comes almost entirely from oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — not intravenous NAD+ itself. In a controlled study, oral NR roughly doubled blood NAD+ in healthy volunteers,[2]and NR has been tested in randomized trials in conditions like Parkinson’s.[3] For intravenous NAD+ specifically, there is no controlled trial demonstrating the anti-aging, energy, or longevity benefits the drips are sold for. See our NAD+ precursors monograph for the route that actually has the data.
That is no longer a gap we have to assert from a literature search of our own. A PRISMA-guided systematic review published in 2026 screened human and rodent intervention studies of NAD-related compounds from 2010 to late 2025 and included 113 of them — 33 human intervention studies, 28 of those randomized. Its finding on the intravenous route is explicit: no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications. The intravenous NAD+ pharmacokinetic pilot below was admitted only as contextual evidence, because it carried no eligible clinical outcomes.[5]
The same review is measured about the oral route rather than promotional: NR and NMN consistently demonstrated biochemical target engagement and were generally well tolerated over weeks to months, but their effects on functional, metabolic, vascular and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific.[5] NAD+ augmentation shows clear biological activity; clinical effectiveness for anti-aging remains inconclusive. That is the honest ceiling for the whole category, drip or capsule.
The one human IV study just measured the blood
The closest thing to direct evidence is a small pharmacokinetic pilot: researchers ran a 6-hour intravenous NAD+ infusion and tracked what happened to it. The finding wasn’t a health benefit — it was that infused NAD+ is rapidly removed from the plasma (no rise in circulating NAD+ for the first two hours, with increased breakdown products excreted in urine by hour six).[1] In other words, the only human study of an IV NAD+ infusion measured its metabolism, not any clinical outcome — and even on metabolism, it complicates the simple “flood your cells with NAD+” pitch.
| What the drip is sold for | What the evidence shows |
|---|---|
| Reverses aging / boosts energy | No controlled trial of IV NAD+ for this |
| Addiction recovery | Only uncontrolled case series — no RCT |
| Floods your cells with NAD+ | Infused NAD+ is cleared from plasma quickly |
| Better than taking a pill | Oral NR/NMN raise blood NAD+ in trials; IV outcomes untested |
NAD+ IV therapy side effects
Until recently the side-effect picture was clinic folklore. A 2026 retrospective review of electronic medical records from a commercial wellness setting changed that, comparing people given four consecutive days of 500 mg NAD+ IV against those given intravenous nicotinamide riboside, with 30 days of follow-up.[4]
The NAD+ IV group reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during the infusions. The NR IV group reported minor tingling in the tongue, jaw and arm, and mild cramping. Symptoms in both groups resolved when the infusion finished. The most telling number is the clock: because the NAD+ symptoms were severe enough to require slowing the drip, NAD+ IV infusions averaged 97 minutes against 37 minutes for NR IV.[4]
On the safety markers the study is reassuring rather than alarming: no significant changes in ALT, AST, hsCRP, BUN/creatinine or TSH. Alkaline phosphatase fell significantly in the NAD+ IV group, with values staying inside normal reference ranges.[4] So the honest summary is that the discomfort is real, common and dose-rate dependent, while short-term harm to liver, kidney or thyroid markers was not detected in this small, retrospective, uncontrolled sample.
The addiction-recovery claim
Some clinics market NAD+ drips heavily for addiction and withdrawal. The published human support for this is uncontrolled case series — descriptive reports without randomization or a placebo group, several from a single connected network.[1] Uncontrolled case reports can motivate a trial; they cannot establish that an expensive infusion treats addiction. Until a controlled trial exists, this claim should be read as marketing, not medicine.
If you care about NAD+, what actually has support
None of this means NAD+ biology is bunk — it means the intravenous drip is the wrong place to spend on it. The human evidence base lives with the oral precursors: NR and NMN reliably raise blood NAD+ in controlled studies, cost a fraction of a drip, and don’t require a clinic visit.[2][3] Whether even that translates into anti-aging outcomes is still an open question — but it’s a far more defensible place to start than an IV bag.
The honest bottom line
NAD+ IV therapy is a textbook case of a real molecule sold through an unproven delivery method at a premium price. There is no controlled trial showing intravenous NAD+ delivers its marketed anti-aging, energy or addiction benefits; the one human IV study found the infused NAD+ is cleared from the blood quickly; and it’s an unregulated, compounded, non-approved service.[1] If NAD+ interests you, the evidence points to the oral-precursor route, not the drip — see our NAD+ precursors guide. For the same regulatory pattern in a different clinic offering — an unapproved product sold confidently for a long list of conditions — see exosome therapy.
